Evidence-based Evaluation and Mechanism of Shenhuang Granules in the Treatment of Sepsis

Recruiting Early Phase 1 Interventional Study
Sepsis
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Early Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
410 (estimated)
Sponsor
The First Affiliated Hospital of Zhejiang Chinese Medical University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Sepsis is a life-threatening organ dysfunction caused by the body's dysfunctional response to infection, most patients require treatment in the ICU, and is the leading cause of death worldwide. Over the years, the development of new drugs for the treatment of sepsis has failed without significant benefit in reducing mortality, and there is currently no effective drug treatment. Therefore, sepsis i…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age ≥18 years old * Meet the diagnostic criteria of sepsis 3.0 guidelines * Sign informed consent. Exclusion Criteria: * Liver or kidney single SOFA score ≥3 points of liver and kidney dysfunction * Death is expected within 48 hours, or SOFA≥15 points, or APACHE II ≥30 point…
Contacts

Wu JianNong, doctor

13777571598

13777571598@163.com

CONTACT

Meng-Yuan Shen, doctor

18261812250

1355759459@qq.com

CONTACT